2020 has been referred to as an unprecedented year for the world in so many ways—the pandemic, the California and Washington fires, the racial justice protests and calls to action—but that didn’t stop the Federal Circuit from setting some highly impactful patent law precedent for the life sciences.

On January 27, Fish attorneys Chad Shear and Teresa Lavoie will discuss some of the most important of these developments.

Where to begin?

• How about venue—and we mean that quite literally. We’ll discuss the impact of Valeant v. Mylan on Hatch-Waxman litigation venue.
• Skinny labeling and inducement. As patent attorneys, we all know that timing and precise language matter—not only in patent claims, but also on drug labels. We’ll discuss the Federal Circuit’s analysis of the facts and holding in GSK v. Teva.
• Many of us experienced our own version of Groundhog Day with respect to our day-to-day lives during the pandemic—each day wasn’t literally the same as the day before, but, wow, did they feel like they were. We’ll explore some patent law Groundhog Day analogies—the doctrine of equivalents in Lilly v. Apotex and 101 patent eligibility in Illumina v. Ariosa.

Join Chad and Teresa as they discuss these issues and many more in the latest installment of Fish & Richardson’s Life Sciences Webinar Series.

Fish & Richardson, P.C. is an accredited CLE provider by the California, New York, and Texas State Continuing Legal Education Boards. (California Provider Number 4933). Fish & Richardson will apply for 1.0 hour of CLE credit in some additional states. Credit will be awarded only to attorneys who report their required CLE states during their registration process and who log in and complete the webinar in its entirety. Note that Fish is unable to grant CLE credit to attendees who listen to the audio portion only.